University of Queensland Researches May Have Found a Universal Biomarker That Identifies Cancer in Various Human Cells in Just 10 Minutes!

This research could lead to a useful liquid biopsy test that would be a powerful new tool for clinical laboratories and anatomic pathologists Cancer researchers have long sought the Holy Grail of diagnostics—a single biomarker that can quickly detect cancer from blood or biopsied tissue. Now, researchers in Australia may have found that treasure. And the preliminary diagnostic test they have developed reportedly can return results in just 10 minutes with 90% accuracy. In a news release,...

UK Scientists Produce Comprehensive Summary of Genes Associated with Cancer in Humans, Making Precision Medicine ‘More Precise’

Expanded ‘Cancer Gene Census’ is expected to accelerate development of new therapeutics and biomarker-based personalized medicine diagnostic tests for disease; could be useful for anatomic pathologists Oncology is one of the fastest-developing fields in precision medicine and use of DNA-based diagnostics. Surgical pathologists are helping many cancer patients benefit from the use of a companion genetic test that shows their tumors are likely to respond to a specific drug or therapy. Consistent...

Recently published White Paper explores effective new ways for clinical labs and pathology groups to reverse the trend of uncollected revenue in an era of higher patient requirements and reimbursement pressures

As a result of the drive toward consumer-driven healthcare, and because of rising health insurance deductibles, patients are increasingly becoming the new payers. Efficient patient access management is now viewed as critical to reversing the resulting trend of uncompensated care, and to meeting the lab’s revenue cycle objectives. As patients take on more risk and assume more of their own healthcare costs, and as registration errors, authorization, and medical necessity continue to contribute...

Results of Harvard Study into Medicare Costs Offers Opportunities for Clinical Laboratories

Harvard’s study of high-cost Medicare patients offers insights into how medical laboratories can help improve early diagnosis, optimize therapies, and monitor chronic disease Clinical laboratories and anatomic pathology groups supporting Medicare patients understand that a small portion of high-cost patients make up the majority of Medicare spending. Between extended treatment, comorbidities, and the complex nature of disease therapies, chronic illnesses have a major impact on healthcare...

PAMA Price Reporting Update: What to Watch for During Data Validation

Starting in July 2019, to comply with PAMA, medical laboratories are expected to analyze their private payer price data to help ensure clean, complete, and accurate reporting by March 31, 2020 Collect. Analyze. Report. Simple enough, except that the devil is in the details, according to experts who conducted a special, daylong PAMA private payer price reporting workshop following the 24th Annual Executive War College on Clinical Laboratory and Pathology Management (EWC) held in New Orleans....

Sonic Healthcare Uses Test Data to Create Shared Savings Opportunities for Clinical Laboratory and Providers

Sonic’s data-driven approach to population health management, based on helping clinicians intervene with patients to control healthcare costs, increases the lab’s revenue Sonic Healthcare USA is using clinical laboratory test data to help its client providers improve population health. This effort also has allowed the Austin, Texas-based lab company to share in the savings one provider client received from the Medicare Shared Savings Program. Using integrated financial and clinical analytics,...